BioNTech's ASCO Showcase Highlights Two Late-Stage Pathways as Financial Runway Lengthens

BioNTech unveils dual late-stage oncology programs at ASCO: a HER2-directed ADC for endometrial cancer and a bispecific immunotherapy for NSCLC, backed by €16.76B cash.

BioNTech entered the ASCO annual meeting with a dual-pronged oncology narrative that goes well beyond the familiar mRNA platform. The German biotech is now pushing two distinct late-stage programmes into the regulatory spotlight—a HER2-directed antibody-drug conjugate for endometrial cancer and a bispecific immunotherapy for lung cancer—while leaning on a €16.76 billion cash pile to fund the transition from pandemic-era earnings to a diversified oncology house.

Shares edged up 0.73% to €82.95 on Monday, extending a weekly gain of nearly 4%. Even so, the stock remains 16.58% lower over twelve months, reflecting the market's cautious stance on the revenue gap that BioNTech must close.

ADC Programme Moves Toward a US Filing

The centrepiece of BioNTech's ASCO presence is Fern-EC-01, a late-stage study evaluating trastuzumab pamirtecan, an experimental antibody-drug conjugate targeting HER2-expressing tumours. The drug, developed jointly with Duality Biologics, pairs a HER2-directed antibody with a topoisomerase I inhibitor payload. In recurrent or treatment-resistant endometrial cancer, where strong HER2 expression signals aggressive disease and a poor prognosis, treatment options are limited.

The study's design is structured for regulatory weight. A larger cohort of around 420 patients with low-to-moderate HER2 expression will be randomised 2:1 to receive either trastuzumab pamirtecan or investigator-choice chemotherapy. The primary endpoint is progression-free survival by independent central review, with overall survival as a key secondary measure. A smaller cohort of about 60 patients with high HER2 expression will receive the drug alone, with the objective response rate as the primary endpoint.

BioNTech and DualityBio plan to submit a registration application in 2026, contingent on regulatory feedback. A fully enrolled cohort from an earlier study in recurrent endometrial cancer already supports the regulatory path. The ASCO presentation, scheduled for 1 June from 9:00 to 12:00 CDT, focuses on the study design rather than new clinical data, but the strategic message is clear: BioNTech is moving programmes toward approval, not just proof-of-concept.

Pumitamig Data Offer Early Read on Bispecific Strategy

Separately, BioNTech and partner Bristol Myers Squibb presented interim results from the global Phase 2 study ROSETTA Lung-02, evaluating pumitamig—a bispecific immunomodulator targeting PD-L1 and VEGF-A—in combination with chemotherapy for previously untreated advanced non-small cell lung cancer.

Data from 40 evaluable patients with a median follow?up of 9.0 months showed a confirmed objective response rate of 63.6% in the non-squamous cohort and 72.7% in the squamous cohort. The sample remains small, but the strategic milestone is that pumitamig is the first PD-(L)1xVEGF bispecific candidate to generate global first-line data. The Phase 3 portion is already underway.

The field is fiercely competitive. In the same ASCO session, Summit Therapeutics presented Phase 3 data for ivonescimab from the HARMONi?6 study, showing a median overall survival advantage of 27.9 months versus 23.7 months over tislelizumab in advanced squamous NSCLC. That sets a high bar for pumitamig as it progresses to larger trials.

Financial Bridge Supports Clinical Ambition

BioNTech's first-quarter 2026 results underscored the costs of transformation. Revenue came in at €118.1 million, while the net loss reached €531.9 million—equivalent to a diluted loss per share of €2.10. The company confirmed its full-year 2026 revenue guidance of €2.0 billion to €2.3 billion.

Yet the balance sheet provides ample room for costly late-stage work. As of end?March 2026, BioNTech held €16.76 billion in cash, cash equivalents and securities, of which €9.94 billion was in cash and cash equivalents. On 7 May, the company authorised a new share buyback programme for American Depositary Shares of up to $1.0 billion, to run until 6 May 2027 and funded from existing cash.

Analyst Confidence Swells Ahead of ASCO

UBS upgraded BioNTech from "Neutral" to "Buy" just before the ASCO presentations, raising the price target from $117 to $135. The bank cited the broadening oncology pipeline as a key valuation lever, underscoring that clinical milestones—not legacy vaccine revenue—now drive the stock.

With more than two dozen trials in mid?to?late stages at ASCO, including 13 ongoing registration-enabling studies, BioNTech's clinical calendar remains the primary catalyst. The market will be watching closely whether early signals from pumitamig and the regulatory design of Fern?EC?01 translate into the first US oncology approvals later this decade.